Scolding N J, Morgan B P, Houston W A, Linington C, Campbell A K, Compston D A
Section of Neurology, University of Wales College of Medicine, Heath Park, Cardiff, UK.
Nature. 1989 Jun 22;339(6226):620-2. doi: 10.1038/339620a0.
Oligodendrocytes synthesize myelin in the central nervous system and maintain it in lamellar sheaths around axons. Techniques for studying oligodendrocyte development in vitro can be used, indirectly, to investigate the myelin injury that occurs in human and experimental demyelinating disease. Cell-mediated immune mechanisms are necessary but not sufficient to induce myelin damage in vivo; more recently complement has also been implicated in the pathogenesis both of multiple sclerosis and experimental allergic encephalomyelitis. Previously we have demonstrated that antibody-independent complement activation occurs in vitro at the oligodendrocyte surface. Here we show that the ensuing oligodendrocyte injury is reversible, and that recovery involves the release of membrane-attack complex-enriched vesicles from the surface of viable cells. The demonstration of morphologically and immunochemically identical vesicles in the cerebrospinal fluid of patients with multiple sclerosis suggests that reversible complement-mediated injury contributes to myelin damage in vivo.
少突胶质细胞在中枢神经系统中合成髓磷脂,并将其维持在轴突周围的板层鞘中。体外研究少突胶质细胞发育的技术可间接用于研究人类和实验性脱髓鞘疾病中发生的髓磷脂损伤。细胞介导的免疫机制对于在体内诱导髓磷脂损伤是必要的,但并不充分;最近,补体也被认为与多发性硬化症和实验性过敏性脑脊髓炎的发病机制有关。此前我们已经证明,在体外少突胶质细胞表面会发生非抗体依赖性补体激活。在此我们表明,随后发生的少突胶质细胞损伤是可逆的,并且恢复过程涉及从存活细胞表面释放富含膜攻击复合物的囊泡。在多发性硬化症患者的脑脊液中发现形态和免疫化学上相同的囊泡,这表明可逆的补体介导的损伤在体内导致了髓磷脂损伤。